JP2010529987A5 - - Google Patents

Info

Publication number

JP2010529987A5

JP2010529987A5 JP2010512217A JP2010512217A JP2010529987A5 JP 2010529987 A5 JP2010529987 A5 JP 2010529987A5 JP 2010512217 A JP2010512217 A JP 2010512217A JP 2010512217 A JP2010512217 A JP 2010512217A JP 2010529987 A5 JP2010529987 A5 JP 2010529987A5

Authority

JP

Japan

Prior art keywords

cells

cell

composition

tissue

bone marrow

Prior art date

2008-06-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 claims description 737
• 238000000034 method Methods 0.000 claims description 289
• 239000000203 mixture Substances 0.000 claims description 272
• 210000001519 tissue Anatomy 0.000 claims description 184
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 153
• 241000282414 Homo sapiens Species 0.000 claims description 131
• 210000001185 bone marrow Anatomy 0.000 claims description 93
• 210000000056 organ Anatomy 0.000 claims description 91
• 229910052760 oxygen Inorganic materials 0.000 claims description 84
• 108010035532 Collagen Proteins 0.000 claims description 78
• 102000008186 Collagen Human genes 0.000 claims description 78
• 229920001436 collagen Polymers 0.000 claims description 78
• 201000010099 disease Diseases 0.000 claims description 77
• 230000001332 colony forming effect Effects 0.000 claims description 75
• 208000035475 disorder Diseases 0.000 claims description 74
• 208000027418 Wounds and injury Diseases 0.000 claims description 70
• 238000011282 treatment Methods 0.000 claims description 70
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 68
• 239000001301 oxygen Substances 0.000 claims description 68
• 230000006378 damage Effects 0.000 claims description 64
• 238000000338 in vitro Methods 0.000 claims description 60
• 210000001082 somatic cell Anatomy 0.000 claims description 60
• 238000010899 nucleation Methods 0.000 claims description 51
• 230000004069 differentiation Effects 0.000 claims description 42
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 40
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 40
• 230000001464 adherent effect Effects 0.000 claims description 40
• 102000004127 Cytokines Human genes 0.000 claims description 38
• 108090000695 Cytokines Proteins 0.000 claims description 38
• 210000002798 bone marrow cell Anatomy 0.000 claims description 36
• 239000011159 matrix material Substances 0.000 claims description 35
• 238000002347 injection Methods 0.000 claims description 34
• 239000007924 injection Substances 0.000 claims description 34
• 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims description 33
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 33
• 102100032819 Integrin alpha-3 Human genes 0.000 claims description 33
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 33
• 208000014674 injury Diseases 0.000 claims description 33
• 238000004519 manufacturing process Methods 0.000 claims description 33
• 206010021143 Hypoxia Diseases 0.000 claims description 32
• 230000001146 hypoxic effect Effects 0.000 claims description 32
• 239000007788 liquid Substances 0.000 claims description 31
• 210000003743 erythrocyte Anatomy 0.000 claims description 28
• 206010061218 Inflammation Diseases 0.000 claims description 26
• 230000004054 inflammatory process Effects 0.000 claims description 26
• 206010016654 Fibrosis Diseases 0.000 claims description 24
• 230000004761 fibrosis Effects 0.000 claims description 24
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 23
• 230000000694 effects Effects 0.000 claims description 22
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 21
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 21
• 238000001727 in vivo Methods 0.000 claims description 21
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 19
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 19
• 210000000130 stem cell Anatomy 0.000 claims description 19
• 230000001133 acceleration Effects 0.000 claims description 18
• 230000001965 increasing effect Effects 0.000 claims description 18
• 230000002829 reductive effect Effects 0.000 claims description 18
• 102100032912 CD44 antigen Human genes 0.000 claims description 17
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 17
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 17
• 102000003729 Neprilysin Human genes 0.000 claims description 17
• 108090000028 Neprilysin Proteins 0.000 claims description 17
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 17
• 230000033115 angiogenesis Effects 0.000 claims description 17
• 230000001363 autoimmune Effects 0.000 claims description 17
• 210000002744 extracellular matrix Anatomy 0.000 claims description 17
• 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 17
• 108010002350 Interleukin-2 Proteins 0.000 claims description 16
• 102000000588 Interleukin-2 Human genes 0.000 claims description 16
• 230000000451 tissue damage Effects 0.000 claims description 16
• 231100000827 tissue damage Toxicity 0.000 claims description 16
• 102000004506 Blood Proteins Human genes 0.000 claims description 15
• 108010017384 Blood Proteins Proteins 0.000 claims description 15
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 15
• 230000009885 systemic effect Effects 0.000 claims description 15
• 102100022749 Aminopeptidase N Human genes 0.000 claims description 14
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 14
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 14
• 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 14
• 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims description 14
• 102100033467 L-selectin Human genes 0.000 claims description 14
• 206010028980 Neoplasm Diseases 0.000 claims description 14
• 210000002950 fibroblast Anatomy 0.000 claims description 14
• 230000006698 induction Effects 0.000 claims description 14
• 230000001939 inductive effect Effects 0.000 claims description 13
• 230000002757 inflammatory effect Effects 0.000 claims description 13
• 230000017423 tissue regeneration Effects 0.000 claims description 13
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 12
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
• 239000011575 calcium Substances 0.000 claims description 12
• 229910052791 calcium Inorganic materials 0.000 claims description 12
• 230000002708 enhancing effect Effects 0.000 claims description 12
• 210000002865 immune cell Anatomy 0.000 claims description 12
• 230000010412 perfusion Effects 0.000 claims description 12
• 238000002054 transplantation Methods 0.000 claims description 12
• 108010094028 Prothrombin Proteins 0.000 claims description 11
• 230000007423 decrease Effects 0.000 claims description 11
• 208000037765 diseases and disorders Diseases 0.000 claims description 11
• 230000028993 immune response Effects 0.000 claims description 11
• 108010012236 Chemokines Proteins 0.000 claims description 10
• 102000019034 Chemokines Human genes 0.000 claims description 10
• 229920000954 Polyglycolide Polymers 0.000 claims description 10
• 238000012423 maintenance Methods 0.000 claims description 10
• 239000004633 polyglycolic acid Substances 0.000 claims description 10
• 230000009467 reduction Effects 0.000 claims description 10
• 108010000499 Thromboplastin Proteins 0.000 claims description 9
• 102000002262 Thromboplastin Human genes 0.000 claims description 9
• 230000004071 biological effect Effects 0.000 claims description 9
• 210000001671 embryonic stem cell Anatomy 0.000 claims description 9
• 230000003394 haemopoietic effect Effects 0.000 claims description 9
• 210000000987 immune system Anatomy 0.000 claims description 9
• 238000002955 isolation Methods 0.000 claims description 9
• 108020004707 nucleic acids Proteins 0.000 claims description 9
• 102000039446 nucleic acids Human genes 0.000 claims description 9
• 150000007523 nucleic acids Chemical class 0.000 claims description 9
• 108010073385 Fibrin Proteins 0.000 claims description 8
• 102000009123 Fibrin Human genes 0.000 claims description 8
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 8
• 108010049003 Fibrinogen Proteins 0.000 claims description 8
• 102000008946 Fibrinogen Human genes 0.000 claims description 8
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
• 108090000190 Thrombin Proteins 0.000 claims description 8
• 238000003501 co-culture Methods 0.000 claims description 8
• 229950003499 fibrin Drugs 0.000 claims description 8
• 229940012952 fibrinogen Drugs 0.000 claims description 8
• 208000028867 ischemia Diseases 0.000 claims description 8
• 108010008217 nidogen Proteins 0.000 claims description 8
• 230000002138 osteoinductive effect Effects 0.000 claims description 8
• 108010025221 plasma protein Z Proteins 0.000 claims description 8
• 230000035755 proliferation Effects 0.000 claims description 8
• 229960004072 thrombin Drugs 0.000 claims description 8
• 102100027378 Prothrombin Human genes 0.000 claims description 7
• 210000001612 chondrocyte Anatomy 0.000 claims description 7
• 230000005764 inhibitory process Effects 0.000 claims description 7
• 230000021633 leukocyte mediated immunity Effects 0.000 claims description 7
• 229940039716 prothrombin Drugs 0.000 claims description 7
• 208000029578 Muscle disease Diseases 0.000 claims description 6
• 208000017442 Retinal disease Diseases 0.000 claims description 6
• 210000001789 adipocyte Anatomy 0.000 claims description 6
• 210000004504 adult stem cell Anatomy 0.000 claims description 6
• 230000002411 adverse Effects 0.000 claims description 6
• 230000004663 cell proliferation Effects 0.000 claims description 6
• 206010012601 diabetes mellitus Diseases 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 239000012634 fragment Substances 0.000 claims description 6
• 230000009931 harmful effect Effects 0.000 claims description 6
• 210000000952 spleen Anatomy 0.000 claims description 6
• 102100022002 CD59 glycoprotein Human genes 0.000 claims description 5
• 102000016942 Elastin Human genes 0.000 claims description 5
• 108010014258 Elastin Proteins 0.000 claims description 5
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 5
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 5
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 5
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
• 101000622137 Homo sapiens P-selectin Proteins 0.000 claims description 5
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
• 102100022297 Integrin alpha-X Human genes 0.000 claims description 5
• 102100025304 Integrin beta-1 Human genes 0.000 claims description 5
• 102000007547 Laminin Human genes 0.000 claims description 5
• 108010085895 Laminin Proteins 0.000 claims description 5
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 5
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
• 102100023472 P-selectin Human genes 0.000 claims description 5
• 102000013566 Plasminogen Human genes 0.000 claims description 5
• 108010051456 Plasminogen Proteins 0.000 claims description 5
• 102000001708 Protein Isoforms Human genes 0.000 claims description 5
• 108010029485 Protein Isoforms Proteins 0.000 claims description 5
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
• 108010017842 Telomerase Proteins 0.000 claims description 5
• 230000015572 biosynthetic process Effects 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 229920002549 elastin Polymers 0.000 claims description 5
• 238000001990 intravenous administration Methods 0.000 claims description 5
• 210000003041 ligament Anatomy 0.000 claims description 5
• 230000001105 regulatory effect Effects 0.000 claims description 5
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
• 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
• 102100023804 Coagulation factor VII Human genes 0.000 claims description 4
• 108010076282 Factor IX Proteins 0.000 claims description 4
• 108010014172 Factor V Proteins 0.000 claims description 4
• 108010023321 Factor VII Proteins 0.000 claims description 4
• 108010054218 Factor VIII Proteins 0.000 claims description 4
• 102000001690 Factor VIII Human genes 0.000 claims description 4
• 108010014173 Factor X Proteins 0.000 claims description 4
• 108010074864 Factor XI Proteins 0.000 claims description 4
• 108010080865 Factor XII Proteins 0.000 claims description 4
• 102000000429 Factor XII Human genes 0.000 claims description 4
• 108010071289 Factor XIII Proteins 0.000 claims description 4
• 102100037362 Fibronectin Human genes 0.000 claims description 4
• 108010067306 Fibronectins Proteins 0.000 claims description 4
• 108090000481 Heparin Cofactor II Proteins 0.000 claims description 4
• 102100030500 Heparin cofactor 2 Human genes 0.000 claims description 4
• 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims description 4
• 102100035792 Kininogen-1 Human genes 0.000 claims description 4
• 102100037369 Nidogen-1 Human genes 0.000 claims description 4
• 108090000113 Plasma Kallikrein Proteins 0.000 claims description 4
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 4
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 4
• 101800004937 Protein C Proteins 0.000 claims description 4
• 102000017975 Protein C Human genes 0.000 claims description 4
• 229940096437 Protein S Drugs 0.000 claims description 4
• 108010066124 Protein S Proteins 0.000 claims description 4
• 102000029301 Protein S Human genes 0.000 claims description 4
• 101800001700 Saposin-D Proteins 0.000 claims description 4
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 4
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 4
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
• 239000004019 antithrombin Substances 0.000 claims description 4
• 230000003683 cardiac damage Effects 0.000 claims description 4
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 4
• 229960004222 factor ix Drugs 0.000 claims description 4
• 229940012413 factor vii Drugs 0.000 claims description 4
• 229940012414 factor viia Drugs 0.000 claims description 4
• 229960000301 factor viii Drugs 0.000 claims description 4
• 229940012444 factor xiii Drugs 0.000 claims description 4
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
• 229920002674 hyaluronan Polymers 0.000 claims description 4
• 229960003160 hyaluronic acid Drugs 0.000 claims description 4
• 230000003463 hyperproliferative effect Effects 0.000 claims description 4
• 230000005931 immune cell recruitment Effects 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 210000003734 kidney Anatomy 0.000 claims description 4
• 208000019423 liver disease Diseases 0.000 claims description 4
• 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
• 229940012957 plasmin Drugs 0.000 claims description 4
• 229960000856 protein c Drugs 0.000 claims description 4
• 230000002797 proteolythic effect Effects 0.000 claims description 4
• 229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
• 230000007838 tissue remodeling Effects 0.000 claims description 4
• 229960005356 urokinase Drugs 0.000 claims description 4
• 108010047303 von Willebrand Factor Proteins 0.000 claims description 4
• 102100036537 von Willebrand factor Human genes 0.000 claims description 4
• 229960001134 von willebrand factor Drugs 0.000 claims description 4
• 102100024210 CD166 antigen Human genes 0.000 claims description 3
• 206010067125 Liver injury Diseases 0.000 claims description 3
• 208000029549 Muscle injury Diseases 0.000 claims description 3
• 208000021642 Muscular disease Diseases 0.000 claims description 3
• 208000028389 Nerve injury Diseases 0.000 claims description 3
• 206010057430 Retinal injury Diseases 0.000 claims description 3
• 230000030833 cell death Effects 0.000 claims description 3
• 230000011748 cell maturation Effects 0.000 claims description 3
• 230000008021 deposition Effects 0.000 claims description 3
• 231100000040 eye damage Toxicity 0.000 claims description 3
• 231100000234 hepatic damage Toxicity 0.000 claims description 3
• 230000008818 liver damage Effects 0.000 claims description 3
• 210000004698 lymphocyte Anatomy 0.000 claims description 3
• 230000008764 nerve damage Effects 0.000 claims description 3
• 230000008816 organ damage Effects 0.000 claims description 3
• 230000003239 periodontal effect Effects 0.000 claims description 3
• 210000002027 skeletal muscle Anatomy 0.000 claims description 3
• 230000037380 skin damage Effects 0.000 claims description 3
• 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 claims description 2
• 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 claims description 2
• 230000006472 autoimmune response Effects 0.000 claims description 2
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
• 210000000750 endocrine system Anatomy 0.000 claims description 2
• 210000003714 granulocyte Anatomy 0.000 claims description 2
• 210000001616 monocyte Anatomy 0.000 claims description 2
• 210000000440 neutrophil Anatomy 0.000 claims description 2
• 230000000241 respiratory effect Effects 0.000 claims description 2
• 230000005757 colony formation Effects 0.000 claims 2
• 239000000853 adhesive Substances 0.000 claims 1
• 230000001070 adhesive effect Effects 0.000 claims 1
• 230000003362 replicative effect Effects 0.000 claims 1
• 239000002609 medium Substances 0.000 description 73
• 206010052428 Wound Diseases 0.000 description 47
• 239000000243 solution Substances 0.000 description 44
• 102000004169 proteins and genes Human genes 0.000 description 43
• 108090000623 proteins and genes Proteins 0.000 description 43
• 235000018102 proteins Nutrition 0.000 description 42
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 40
• 241000700159 Rattus Species 0.000 description 40
• 210000003491 skin Anatomy 0.000 description 40
• 239000000499 gel Substances 0.000 description 38
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 37
• 239000000047 product Substances 0.000 description 35
• 239000007787 solid Substances 0.000 description 32
• 239000003636 conditioned culture medium Substances 0.000 description 31
• 210000004369 blood Anatomy 0.000 description 29
• 239000008280 blood Substances 0.000 description 29
• 210000002216 heart Anatomy 0.000 description 29
• 230000008929 regeneration Effects 0.000 description 28
• 238000011069 regeneration method Methods 0.000 description 28
• 210000002808 connective tissue Anatomy 0.000 description 27
• 230000004217 heart function Effects 0.000 description 26
• 230000000735 allogeneic effect Effects 0.000 description 25
• 239000003981 vehicle Substances 0.000 description 25
• 206010061216 Infarction Diseases 0.000 description 24
• 230000007574 infarction Effects 0.000 description 24
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 23
• 239000006285 cell suspension Substances 0.000 description 21
• XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 description 21
• 230000000747 cardiac effect Effects 0.000 description 20
• 229910052757 nitrogen Inorganic materials 0.000 description 20
• 230000008439 repair process Effects 0.000 description 20
• 239000000126 substance Substances 0.000 description 20
• 238000003556 assay Methods 0.000 description 19
• 230000007774 longterm Effects 0.000 description 19
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
• 230000002861 ventricular Effects 0.000 description 18
• 229930182816 L-glutamine Natural products 0.000 description 17
• 206010000891 acute myocardial infarction Diseases 0.000 description 17
• 238000004113 cell culture Methods 0.000 description 17
• 230000008859 change Effects 0.000 description 17
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 16
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 16
• 230000006872 improvement Effects 0.000 description 16
• 239000012528 membrane Substances 0.000 description 16
• 230000002107 myocardial effect Effects 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 15
• 108020003175 receptors Proteins 0.000 description 15
• 239000006228 supernatant Substances 0.000 description 15
• 239000012737 fresh medium Substances 0.000 description 14
• 208000010125 myocardial infarction Diseases 0.000 description 14
• 210000002966 serum Anatomy 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 13
• 230000012010 growth Effects 0.000 description 13
• 239000003102 growth factor Substances 0.000 description 13
• 108010070145 interleukin-18 binding protein Proteins 0.000 description 13
• 102000044166 interleukin-18 binding protein Human genes 0.000 description 13
• 238000013507 mapping Methods 0.000 description 13
• 239000013642 negative control Substances 0.000 description 13
• 102000045246 noggin Human genes 0.000 description 13
• 108700007229 noggin Proteins 0.000 description 13
• 230000037390 scarring Effects 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• 108010025020 Nerve Growth Factor Proteins 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• 230000001143 conditioned effect Effects 0.000 description 12
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
• 229940053128 nerve growth factor Drugs 0.000 description 12
• 230000001228 trophic effect Effects 0.000 description 12
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 11
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
• 239000007995 HEPES buffer Substances 0.000 description 11
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 11
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 11
• 102000004889 Interleukin-6 Human genes 0.000 description 11
• 108090001005 Interleukin-6 Proteins 0.000 description 11
• 230000006052 T cell proliferation Effects 0.000 description 11
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 11
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
• 238000012258 culturing Methods 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 239000007789 gas Substances 0.000 description 11
• 230000035876 healing Effects 0.000 description 11
• 210000005003 heart tissue Anatomy 0.000 description 11
• 229940100601 interleukin-6 Drugs 0.000 description 11
• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 230000001737 promoting effect Effects 0.000 description 11
• 230000028327 secretion Effects 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 238000005259 measurement Methods 0.000 description 10
• 239000003226 mitogen Substances 0.000 description 10
• 239000008188 pellet Substances 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 208000023275 Autoimmune disease Diseases 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 9
• 239000012980 RPMI-1640 medium Substances 0.000 description 9
• 210000000988 bone and bone Anatomy 0.000 description 9
• 210000002449 bone cell Anatomy 0.000 description 9
• 241000283690 Bos taurus Species 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 239000006143 cell culture medium Substances 0.000 description 8
• 230000008602 contraction Effects 0.000 description 8
• 239000012510 hollow fiber Substances 0.000 description 8
• 238000003384 imaging method Methods 0.000 description 8
• 208000026278 immune system disease Diseases 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 229960004857 mitomycin Drugs 0.000 description 8
• 210000004165 myocardium Anatomy 0.000 description 8
• 230000001172 regenerating effect Effects 0.000 description 8
• 238000002603 single-photon emission computed tomography Methods 0.000 description 8
• 208000011580 syndromic disease Diseases 0.000 description 8
• 230000008733 trauma Effects 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 108091006905 Human Serum Albumin Proteins 0.000 description 7
• 102000008100 Human Serum Albumin Human genes 0.000 description 7
• 102000035195 Peptidases Human genes 0.000 description 7
• 108091005804 Peptidases Proteins 0.000 description 7
• 239000004365 Protease Substances 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 210000002615 epidermis Anatomy 0.000 description 7
• 210000004700 fetal blood Anatomy 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 208000027866 inflammatory disease Diseases 0.000 description 7
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
• 238000002156 mixing Methods 0.000 description 7
• 230000009826 neoplastic cell growth Effects 0.000 description 7
• -1 polysiloxane Polymers 0.000 description 7
• 230000003716 rejuvenation Effects 0.000 description 7
• 231100000241 scar Toxicity 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 230000002792 vascular Effects 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 102000004877 Insulin Human genes 0.000 description 6
• 108090001061 Insulin Proteins 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
• 102000004338 Transferrin Human genes 0.000 description 6
• 108090000901 Transferrin Proteins 0.000 description 6
• 108010023082 activin A Proteins 0.000 description 6
• 239000012574 advanced DMEM Substances 0.000 description 6
• 238000002659 cell therapy Methods 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 230000007812 deficiency Effects 0.000 description 6
• 210000004207 dermis Anatomy 0.000 description 6
• 230000002500 effect on skin Effects 0.000 description 6
• 230000010437 erythropoiesis Effects 0.000 description 6
• 229940125396 insulin Drugs 0.000 description 6
• 210000005240 left ventricle Anatomy 0.000 description 6
• 230000000394 mitotic effect Effects 0.000 description 6
• 210000003205 muscle Anatomy 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 229910052711 selenium Inorganic materials 0.000 description 6
• 239000011669 selenium Substances 0.000 description 6
• 239000012581 transferrin Substances 0.000 description 6
• 230000029663 wound healing Effects 0.000 description 6
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 5
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 5
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
• 108090000171 Interleukin-18 Proteins 0.000 description 5
• 102000003810 Interleukin-18 Human genes 0.000 description 5
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
• 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
• 108010047620 Phytohemagglutinins Proteins 0.000 description 5
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 5
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 5
• 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 5
• 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 5
• 230000032683 aging Effects 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 239000000427 antigen Substances 0.000 description 5
• 102000036639 antigens Human genes 0.000 description 5
• 108091007433 antigens Proteins 0.000 description 5
• 230000005784 autoimmunity Effects 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 210000001772 blood platelet Anatomy 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 5
• 230000022131 cell cycle Effects 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 238000009295 crossflow filtration Methods 0.000 description 5
• 239000008121 dextrose Substances 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 230000014511 neuron projection development Effects 0.000 description 5
• 239000012466 permeate Substances 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 230000001885 phytohemagglutinin Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 210000000278 spinal cord Anatomy 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
• 108020004463 18S ribosomal RNA Proteins 0.000 description 4
• 208000029462 Immunodeficiency disease Diseases 0.000 description 4
• 102000003815 Interleukin-11 Human genes 0.000 description 4
• 108090000177 Interleukin-11 Proteins 0.000 description 4
• 108010002586 Interleukin-7 Proteins 0.000 description 4
• 102000000704 Interleukin-7 Human genes 0.000 description 4
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
• 102000018697 Membrane Proteins Human genes 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 102000004230 Neurotrophin 3 Human genes 0.000 description 4
• 108090000742 Neurotrophin 3 Proteins 0.000 description 4
• GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
• 206010072170 Skin wound Diseases 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 206010052779 Transplant rejections Diseases 0.000 description 4
• 208000038016 acute inflammation Diseases 0.000 description 4
• 230000006022 acute inflammation Effects 0.000 description 4
• 230000004888 barrier function Effects 0.000 description 4
• 239000007853 buffer solution Substances 0.000 description 4
• 239000000512 collagen gel Substances 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 239000012141 concentrate Substances 0.000 description 4
• 239000012228 culture supernatant Substances 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 210000001339 epidermal cell Anatomy 0.000 description 4
• 230000007717 exclusion Effects 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 239000012595 freezing medium Substances 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 230000011132 hemopoiesis Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 229940074383 interleukin-11 Drugs 0.000 description 4
• 229940100994 interleukin-7 Drugs 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 4
• 230000000926 neurological effect Effects 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 229940032018 neurotrophin 3 Drugs 0.000 description 4
• 210000001428 peripheral nervous system Anatomy 0.000 description 4
• 230000000770 proinflammatory effect Effects 0.000 description 4
• 239000002994 raw material Substances 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 238000007634 remodeling Methods 0.000 description 4
• 102000014452 scavenger receptors Human genes 0.000 description 4
• 108010078070 scavenger receptors Proteins 0.000 description 4
• 208000017520 skin disease Diseases 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 208000020431 spinal cord injury Diseases 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 239000012134 supernatant fraction Substances 0.000 description 4
• 230000001502 supplementing effect Effects 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 210000003954 umbilical cord Anatomy 0.000 description 4
• 239000011534 wash buffer Substances 0.000 description 4
• 102100022987 Angiogenin Human genes 0.000 description 3
• 208000035143 Bacterial infection Diseases 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 208000004434 Calcinosis Diseases 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 206010017533 Fungal infection Diseases 0.000 description 3
• 208000007465 Giant cell arteritis Diseases 0.000 description 3
• 208000015023 Graves' disease Diseases 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 108090001007 Interleukin-8 Proteins 0.000 description 3
• 102000004890 Interleukin-8 Human genes 0.000 description 3
• 208000034693 Laceration Diseases 0.000 description 3
• 208000031888 Mycoses Diseases 0.000 description 3
• 238000011887 Necropsy Methods 0.000 description 3
• 206010029113 Neovascularisation Diseases 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 108010025435 Permacol Proteins 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 108090000631 Trypsin Proteins 0.000 description 3
• 102000004142 Trypsin Human genes 0.000 description 3
• 208000024248 Vascular System injury Diseases 0.000 description 3
• 208000012339 Vascular injury Diseases 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 238000005299 abrasion Methods 0.000 description 3
• 238000000540 analysis of variance Methods 0.000 description 3
• 108010072788 angiogenin Proteins 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 208000022362 bacterial infectious disease Diseases 0.000 description 3
• 239000007640 basal medium Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 238000009835 boiling Methods 0.000 description 3
• 210000001736 capillary Anatomy 0.000 description 3
• 210000000845 cartilage Anatomy 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 210000004351 coronary vessel Anatomy 0.000 description 3
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 230000001627 detrimental effect Effects 0.000 description 3
• 238000002592 echocardiography Methods 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 210000003709 heart valve Anatomy 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 238000007489 histopathology method Methods 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 230000007813 immunodeficiency Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 238000007726 management method Methods 0.000 description 3
• 210000003716 mesoderm Anatomy 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 230000000921 morphogenic effect Effects 0.000 description 3
• 206010028417 myasthenia gravis Diseases 0.000 description 3
• 235000016709 nutrition Nutrition 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 230000011164 ossification Effects 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• 229920002492 poly(sulfone) Polymers 0.000 description 3
• 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 3
• 229920001296 polysiloxane Polymers 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000011552 rat model Methods 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 210000003289 regulatory T cell Anatomy 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 230000009758 senescence Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 238000004114 suspension culture Methods 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 206010043207 temporal arteritis Diseases 0.000 description 3
• 210000002435 tendon Anatomy 0.000 description 3
• 239000012588 trypsin Substances 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 2
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
• 108010082126 Alanine transaminase Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
• 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 241000251204 Chimaeridae Species 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 108050005238 Collagenase 3 Proteins 0.000 description 2
• 102100027995 Collagenase 3 Human genes 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102000012192 Cystatin C Human genes 0.000 description 2
• 108010061642 Cystatin C Proteins 0.000 description 2
• 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 2
• 208000010201 Exanthema Diseases 0.000 description 2
• 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 229940123037 Glucocorticoid antagonist Drugs 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 229920002683 Glycosaminoglycan Polymers 0.000 description 2
• 208000024869 Goodpasture syndrome Diseases 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
• 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 208000005230 Leg Ulcer Diseases 0.000 description 2
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
• 102000008072 Lymphokines Human genes 0.000 description 2
• 108010074338 Lymphokines Proteins 0.000 description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
• 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 2
• 101150114527 Nkx2-5 gene Proteins 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• 108010067787 Proteoglycans Proteins 0.000 description 2
• 102000016611 Proteoglycans Human genes 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 102000005937 Tropomyosin Human genes 0.000 description 2
• 108010030743 Tropomyosin Proteins 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 208000025609 Urogenital disease Diseases 0.000 description 2
• 208000033774 Ventricular Remodeling Diseases 0.000 description 2
• 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000009692 acute damage Effects 0.000 description 2
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 238000004115 adherent culture Methods 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 239000003855 balanced salt solution Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 210000002960 bfu-e Anatomy 0.000 description 2
• 230000002457 bidirectional effect Effects 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 230000002308 calcification Effects 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000002975 chemoattractant Substances 0.000 description 2
• 208000016532 chronic granulomatous disease Diseases 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 230000009850 completed effect Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 229910003460 diamond Inorganic materials 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• 230000035487 diastolic blood pressure Effects 0.000 description 2
• 208000010643 digestive system disease Diseases 0.000 description 2
• 238000002845 discoloration Methods 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 201000003511 ectopic pregnancy Diseases 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 230000007159 enucleation Effects 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 230000000925 erythroid effect Effects 0.000 description 2
• 201000005884 exanthem Diseases 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 210000000416 exudates and transudate Anatomy 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 230000001815 facial effect Effects 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 208000018685 gastrointestinal system disease Diseases 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000003635 glucocorticoid antagonist Substances 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 208000018706 hematopoietic system disease Diseases 0.000 description 2
• 235000012907 honey Nutrition 0.000 description 2
• 102000044890 human EPO Human genes 0.000 description 2
• 230000005965 immune activity Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 239000002955 immunomodulating agent Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000003601 intercostal effect Effects 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000002934 lysing effect Effects 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
• 229960003248 mifepristone Drugs 0.000 description 2
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 239000007758 minimum essential medium Substances 0.000 description 2
• 230000001095 motoneuron effect Effects 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 210000002241 neurite Anatomy 0.000 description 2
• 239000001272 nitrous oxide Substances 0.000 description 2
• 210000003924 normoblast Anatomy 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 230000004819 osteoinduction Effects 0.000 description 2
• 230000032696 parturition Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 238000009832 plasma treatment Methods 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 239000002985 plastic film Substances 0.000 description 2
• 201000003144 pneumothorax Diseases 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920005597 polymer membrane Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000009597 pregnancy test Methods 0.000 description 2
• 230000001023 pro-angiogenic effect Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 206010037844 rash Diseases 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000000250 revascularization Effects 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• 238000005549 size reduction Methods 0.000 description 2
• 208000013363 skeletal muscle disease Diseases 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000035488 systolic blood pressure Effects 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 210000002229 urogenital system Anatomy 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• JCVDICFLPGDHAT-MLKPTWBGSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-3-(tritritiomethyl)pyrimidine-2,4-dione Chemical compound [3H]C([3H])([3H])n1c(=O)c(C)cn([C@H]2C[C@H](O)[C@@H](CO)O2)c1=O JCVDICFLPGDHAT-MLKPTWBGSA-N 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 108010023728 Alloderm Proteins 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 108010001781 Apligraf Proteins 0.000 description 1
• 208000002109 Argyria Diseases 0.000 description 1
• 208000000104 Arthus reaction Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 206010003671 Atrioventricular Block Diseases 0.000 description 1
• 206010003677 Atrioventricular block second degree Diseases 0.000 description 1
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
• 201000008162 B cell deficiency Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 101710129634 Beta-nerve growth factor Proteins 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 102100025222 CD63 antigen Human genes 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102100035882 Catalase Human genes 0.000 description 1
• 108010053835 Catalase Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 229920000298 Cellophane Polymers 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
• 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
• 229920001287 Chondroitin sulfate Polymers 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000001187 Collagen Type III Human genes 0.000 description 1
• 108010069502 Collagen Type III Proteins 0.000 description 1
• 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 206010010996 Corneal degeneration Diseases 0.000 description 1
• 201000000057 Coronary Stenosis Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000000280 Cyclic neutropenia Diseases 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 206010056340 Diabetic ulcer Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000019872 Drug Eruptions Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 206010063044 Ectopic kidney Diseases 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 208000035874 Excoriation Diseases 0.000 description 1
• 208000024720 Fabry Disease Diseases 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000025499 G6PD deficiency Diseases 0.000 description 1
• 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
• 206010019909 Hernia Diseases 0.000 description 1
• 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
• 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000621344 Homo sapiens Protein Wnt-2 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102100025323 Integrin alpha-1 Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
• 102000003777 Interleukin-1 beta Human genes 0.000 description 1
• 108090000193 Interleukin-1 beta Proteins 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
• 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 102000013264 Interleukin-23 Human genes 0.000 description 1
• 108010065637 Interleukin-23 Proteins 0.000 description 1
• 208000005615 Interstitial Cystitis Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 241001026509 Kata Species 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 208000035719 Maculopathy Diseases 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 208000020128 Mitral stenosis Diseases 0.000 description 1
• 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 102000003505 Myosin Human genes 0.000 description 1
• 108060008487 Myosin Proteins 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000016222 Pancreatic disease Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
• 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
• 108010065084 Phosphorylase a Proteins 0.000 description 1
• 206010036030 Polyarthritis Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 208000012287 Prolapse Diseases 0.000 description 1
• 102100022805 Protein Wnt-2 Human genes 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 241001233278 Scalopus aquaticus Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 241000219289 Silene Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 201000001322 T cell deficiency Diseases 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 208000003441 Transfusion reaction Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 102000013394 Troponin I Human genes 0.000 description 1
• 108010065729 Troponin I Proteins 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000036982 action potential Effects 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000002009 allergenic effect Effects 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 229940125708 antidiabetic agent Drugs 0.000 description 1
• 239000002543 antimycotic Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 208000006424 autoimmune oophoritis Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 208000029162 bladder disease Diseases 0.000 description 1
• 238000004061 bleaching Methods 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 238000004159 blood analysis Methods 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 238000009640 blood culture Methods 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
• JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 231100001012 cardiac lesion Toxicity 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 230000003848 cartilage regeneration Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000012578 cell culture reagent Substances 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010094 cellular senescence Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 231100000481 chemical toxicant Toxicity 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 210000003040 circulating cell Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 238000012733 comparative method Methods 0.000 description 1
• 201000002388 complement deficiency Diseases 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 238000011026 diafiltration Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 210000003981 ectoderm Anatomy 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000013013 elastic material Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 208000030172 endocrine system disease Diseases 0.000 description 1
• 210000001900 endoderm Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 208000010227 enterocolitis Diseases 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 210000003013 erythroid precursor cell Anatomy 0.000 description 1
• 230000000913 erythropoietic effect Effects 0.000 description 1
• PEBKBUOHNYJUKF-UHFFFAOYSA-N ethanol;2-sulfanylethanol Chemical compound CCO.OCCS PEBKBUOHNYJUKF-UHFFFAOYSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 210000003499 exocrine gland Anatomy 0.000 description 1
• 210000000646 extraembryonic cell Anatomy 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• 210000003195 fascia Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 208000001031 fetal erythroblastosis Diseases 0.000 description 1
• 230000004578 fetal growth Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 210000003953 foreskin Anatomy 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000012213 gelatinous substance Substances 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 210000001654 germ layer Anatomy 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 208000011316 hemodynamic instability Diseases 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 238000011327 histological measurement Methods 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000006058 immune tolerance Effects 0.000 description 1
• 201000008269 immune-complex glomerulonephritis Diseases 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000000954 inflammatory inducer Substances 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 239000007925 intracardiac injection Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 229940113601 irrigation solution Drugs 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• 239000008274 jelly Substances 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 231100000516 lung damage Toxicity 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
• 229960002140 medetomidine Drugs 0.000 description 1
• 229920002529 medical grade silicone Polymers 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 208000006887 mitral valve stenosis Diseases 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 208000000638 myeloperoxidase deficiency Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 208000024691 pancreas disease Diseases 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000002135 phase contrast microscopy Methods 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 230000033885 plasminogen activation Effects 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 208000030428 polyarticular arthritis Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000003651 pro-proliferative effect Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 description 1
• 238000003498 protein array Methods 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 239000003237 recreational drug Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000037309 reepithelialization Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• 230000008263 repair mechanism Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000008943 replicative senescence Effects 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 239000012465 retentate Substances 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 210000005241 right ventricle Anatomy 0.000 description 1
• 231100000279 safety data Toxicity 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000007390 skin biopsy Methods 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 238000013223 sprague-dawley female rat Methods 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 238000007892 surgical revascularization Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
• 201000005990 thymic dysplasia Diseases 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 229940033618 tisseel Drugs 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 238000002627 tracheal intubation Methods 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 229960001005 tuberculin Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
• 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 229910021642 ultra pure water Inorganic materials 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 239000012498 ultrapure water Substances 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 208000026533 urinary bladder disease Diseases 0.000 description 1
• 239000012808 vapor phase Substances 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 231100000747 viability assay Toxicity 0.000 description 1
• 238000003026 viability measurement method Methods 0.000 description 1
• 239000003190 viscoelastic substance Substances 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1
• 230000037303 wrinkles Effects 0.000 description 1